Last reviewed · How we verify
NCT06823817: QCCA
Quality Control of Colposcopy Application
trial testing colpscope in Cervical Cancers in 10,000 participants. Completed in 1 January 2025.
1 January 2025
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 January 2015 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
Drugs / interventions tested
- colpscope
Conditions studied
- Cervical Cancers — all drugs for Cervical Cancers →
- Cervical Intraepithelial Neoplasia (CIN) — all drugs for Cervical Intraepithelial Neoplasia (CIN) →
Sponsor
Peking Union Medical College Hospital
Who can join
18 and older, female only, with Cervical Cancers or Cervical Intraepithelial Neoplasia (CIN). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Colposcopy has become an important link and tool in the prevention and treatment of cervical cancer. The quality and pathological assessment of colposcopy is a key point in follow-up and treatment.The main purpose of this study was to analyze the correlation between colposcopy indications and pathological findings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06823817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancers
Currently open trials in the same condition.
- NCT06910657 — IDOV-Immune for Advanced Solid Tumors · Phase 1 · recruiting
- NCT07130240 — Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 a · Phase 2 · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06867445 — Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence · NA · recruiting
- NCT07003620 — Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial · Phase 2 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06823817 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06823817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing